REGENERON PHARMAC.DL-,001
REGENERON PHARMAC.DL-,001/ US75886F1075 /
RGO
|
08/11/2024 08:04:51
|
Var.
+1.80
|
Volume |
Denaro20:22:20 |
Lettera20:22:20 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
|
761.60EUR
|
+0.24%
|
0
Fatturato: 0.00 |
769.60Quantità in denaro: 180 |
771.20Quantità in lettera: 180 |
84.09 bill.EUR |
- |
- |
Descrizione business
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Dr. Leonard S. Schleifer |
| Consiglio di amministrazione |
| Robert E. Landry, Dr. George D. Yancopoulos |
| Consiglio di sorveglianza |
| Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D. |
Dati aziendali
| Name: |
Regeneron Pharmaceuticals Inc. |
| Indirizzo: |
777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA |
| Telefono: |
+1-914-847-7000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
is.gd/sEAmh8 |
| Industria: |
Biotechnology |
| Settore: |
Biotechnology |
| Sub settore: |
Biotechnology |
| Fine dell'anno finanziario: |
31/12 |
| Flottante libero: |
68.40% |
| Data dell'IPO: |
12/04/1991 |
Rapporti con gli investitori
| Name: |
- |
| IR telefono: |
+1-914-847-7741 |
| IR Fax: |
- |
| IR e-mail: |
invest@regeneron.com
|
Principali azionisti
| Altri |
|
50.26% |
| FMR LLC. |
|
9.52% |
| Vanguard Group |
|
8.16% |
| BlackRock Inc. |
|
7.96% |
| JP Morgan Chase & Co. |
|
6.67% |
| Capital World Investors |
|
4.73% |
| State Street Corporation |
|
4.52% |
| Capital International Investors |
|
2.69% |
| Dodge & Cox |
|
2.18% |
| Altri |
|
3.30% |
